Genmab A/S (NASDAQ:GMAB) Given Average Rating of “Hold” by Brokerages

Shares of Genmab A/S (NASDAQ:GMABGet Rating) have received a consensus rating of “Hold” from the seventeen ratings firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $479.57.

A number of analysts have commented on the company. Berenberg Bank upgraded Genmab A/S from a “sell” rating to a “hold” rating in a research report on Friday. Cowen began coverage on shares of Genmab A/S in a research note on Monday, May 2nd. They issued a “market perform” rating and a $38.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Genmab A/S in a research report on Thursday, March 17th. Zacks Investment Research lowered shares of Genmab A/S from a “hold” rating to a “sell” rating in a research report on Thursday, January 20th. Finally, SVB Leerink cut their price objective on Genmab A/S from $42.00 to $39.00 and set a “market perform” rating for the company in a research report on Thursday, February 17th.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares during the period. Stifel Financial Corp lifted its stake in shares of Genmab A/S by 1.1% during the 4th quarter. Stifel Financial Corp now owns 1,209,423 shares of the company’s stock worth $47,844,000 after purchasing an additional 12,587 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Genmab A/S by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,088,500 shares of the company’s stock worth $39,382,000 after purchasing an additional 14,100 shares during the period. Hardman Johnston Global Advisors LLC lifted its stake in shares of Genmab A/S by 0.9% during the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 1,079,269 shares of the company’s stock worth $47,164,000 after purchasing an additional 10,013 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Genmab A/S by 63.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 869,221 shares of the company’s stock worth $31,448,000 after purchasing an additional 338,902 shares during the period. 5.92% of the stock is currently owned by institutional investors.

Shares of NASDAQ GMAB opened at $29.32 on Friday. The stock has a market capitalization of $19.27 billion, a price-to-earnings ratio of 40.16, a price-to-earnings-growth ratio of 1.27 and a beta of 0.98. Genmab A/S has a 52 week low of $27.42 and a 52 week high of $49.07. The firm has a 50-day moving average price of $34.86 and a 200 day moving average price of $36.52.

Genmab A/S (NASDAQ:GMABGet Rating) last posted its quarterly earnings results on Wednesday, February 16th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The company had revenue of $402.74 million during the quarter, compared to the consensus estimate of $387.16 million. Genmab A/S had a net margin of 35.58% and a return on equity of 14.23%. Research analysts forecast that Genmab A/S will post 0.77 earnings per share for the current fiscal year.

Genmab A/S Company Profile (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.